A Multicenter, Randomized, Open-Label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients with Advanced Multiple Myeloma
The study isbeing done to find out what effects, good and/or bad, the study drug, ARRY-520 with or without carfilzomib, has on a participant and his or her Multiple Myeloma.
≥ 18 years of age
Confirmed multiple myeloma with treatment history must include all of
-Received at least 2 prior treatment regimens, including bortezomib and an IMiD
(e.g., lenalidomide, thalidomide, pomalidomide). Induction therapy and stem cell
transplant ± maintenance are to be considered as a single regimen.
-Refractory disease, defined as documented disease progression during or within
60 days of completing the last myeloma therapy.
Measurable Multiple Myeloma disease which includes certain levels of IgM, urinary light chain secretion, and serum free light chain.
Adequate lab values, liver and kidney function, and heart function
No current diagnosis pulmonary hypertension
No pregnant or breastfeeding women
No autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to study start.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participation in the study will last until participant decides to stop, has unacceptable side effects, multiple myeloma gets worse, the investigator decides it is best to stop, or the sponsor ends the study.
Clinical Trials Information Line: Phone 503-494-1080 or email@example.com
Array BioPharma Inc.